Aspira Women's Health

Aspira Women's Health develops and commercializes high-value, multi-marker, diagnostic tests that address unmet needs in gynecologic oncology and women’s health. The company is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.

Its OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. They focus on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.

Aspira Women's Health was founded in 1993 and is headquartered in Austin, Texas, USA.

Aspira Women's Health headquartered in United States, North America, operates in the Biotechnology, Health Care, Women's, Health Diagnostics, Oncology sector. The company focuses on Biotechnology and has secured $23.7B in funding across 160 round(s). With a team of 51-100 employees, Aspira Women's Health is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Aspira Women's Health, raised $43.0M. Discover more about their projects, partnerships, and impact on our platform.